ATP binding cassette subfamily C member 2Genealiases: ABC30 · CMOAT · DJS · MRP2 · cMRP
Q-omics provides the consensus-scored ABCC2 profile across patient tissues and cancer cell-line models. ABCC2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ABCC2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ABCC2 RNA expression shows 19,431 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where ABCC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCC2 survival associations across molecular data types. ABCC2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCC2 RNA expression–survival associations across cancer types. High ABCC2 expression shows unfavorable associations in LUAD, HNSC, BRCA, SKCM, KIRP and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ABCC2 RNA expression.
This table summarizes ABCC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABCC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCC2 shows lower tumor expression in THCA, KICH and BLCA and higher tumor expression in KIRC, HNSC and COAD. The KIRC box plot shows higher ABCC2 RNA expression in tumor versus normal tissue (log2 FC = +1.747, t-test p < 0.001).
This table shows molecular features associated with ABCC2 in patient tissues and cancer cell lines. In patient samples, ABCC2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SKIN.
